欧洲药物建模软件市场预测至 2027 年 - COVID-19 影响和分析 - 按产品类型(数据库、软件等);与应用(药物发现与开发、计算生理医学、疾病建模、医学影像、药物靶点预测分析、仿真软件、细胞仿真等)

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027


No. of Pages: 108    |    Report Code: TIPRE00013989    |    Category: Technology, Media and Telecommunications

Europe Drug Modelling Software Market

市场介绍

药物建模已成为药物设计过程中的重要工具。基于软件的药物发现和开发方法在新药开发中发挥着关键作用。基于软件的方法,如分子建模、基于结构的药物设计、基于结构的虚拟筛选、配体相互作用和分子动力学被认为是研究药物药代动力学和药效学特性的有力工具。这些方法快速、准确,并为实验结果和作用机制提供了有价值的见解。此外,适当实施这些技术可能有助于降低药物设计和开发的成本。

市场概况和动态

欧洲药物建模软件市场预计将从 2019 年的 18.2699 亿美元增至 2027 年的 32.1594 亿美元。市场预计2019 年至 2027 年复合年增长率为 7.6%。在药物发现中越来越多地采用计算机建模工具以及药物发现的经济负担的增加是预计推动欧洲药物建模软件市场增长的主要因素。然而,市场可能会受到预测期内缺乏数据标准化等风险因素的影响。

关键细分市场

从产品类型来看,2019年欧洲药物建模软件市场中软件领域占据最大份额。从应用来看,药物发现2019 年欧洲药物建模软件市场中,药物建模和开发领域占据最大份额。

主要来源和上市公司

与欧洲药物建模软件市场报告相关的几个主要一手和二手来源是欧洲制药工业和协会联合会 (EFPIA)、欧洲药品管理局 (EMA)、

购买报告的理由

< /span>

  • 它提供了对欧洲药物建模软件市场格局的了解,并确定了最有可能保证强劲回报的药物建模软件细分市场。< /li>
  • 它通过了解欧洲药物建模软件市场不断变化的竞争格局来指导保持领先地位。
  • 它有助于高效规划通过识别最有可能销售的细分市场,在药物建模软件市场上进行并购和合作伙伴关系
  • 它通过洞察力和全面的分析来促进明智的业务决策欧洲药物建模软件市场各个细分市场的药物建模软件市场表现。
  • 它提供了基于各个细分市场的药物建模软件市场收入预测,从2019 年至 2027 年。

欧洲药物建模软件市场细分

< strong>按产品类型

  • 数据库
  • 软件
  • 其他

 

按应用

  • 药物发现与开发
  • 计算生理医学< /li>
  • 疾病模型
  • 医学成像
  • 药物靶点的预测分析
  • 仿真软件
  • 细胞仿真
  • 其他

按国家/地区

  • 德国
  • < span>法国
  • 英国
  • 意大利
  • 西班牙< /span>

公司简介

  • Crown Bioscience Inc(JSR生命科学) )
  • Genedata AG
  • Biognos AB
  • Dassault Systé;消息
  • Acellera


Europe Drug Modelling Software Strategic Insights

Strategic insights for Europe Drug Modelling Software involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-drug-modelling-software-market-strategic-framework.webp
Get more information on this report

Europe Drug Modelling Software Report Scope

Report Attribute Details
Market size in 2019 US$ 1,826.99 Million
Market Size by 2027 US$ 3,215.94 Million
Global CAGR (2019 - 2027) 7.6%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By 产品类型
  • 数据库
  • 软件
By 应用
  • 药物发现和开发
  • 计算生理医学
  • 疾病建模
  • 医学成像
  • 药物靶点的预测分析
  • 模拟软件
  • 细胞模拟
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Crown Bioscience Inc (JSR life science)
  • Genedata AG
  • Biognos AB
  • Dassault Systèmes
  • Acellera
  • Get more information on this report

    Europe Drug Modelling Software Regional Insights

    The regional scope of Europe Drug Modelling Software refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-drug-modelling-software-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Drug Modelling Software Market

    The List of Companies - Europe Drug Modelling Software Market

    1. Crown Bioscience Inc (JSR life science)
    2. Genedata AG
    3. Biognos AB
    4. Dassault Systèmes
    5. Acellera
    Frequently Asked Questions
    How big is the Europe Drug Modelling Software Market?

    The Europe Drug Modelling Software Market is valued at US$ 1,826.99 Million in 2019, it is projected to reach US$ 3,215.94 Million by 2027.

    What is the CAGR for Europe Drug Modelling Software Market by (2019 - 2027)?

    As per our report Europe Drug Modelling Software Market, the market size is valued at US$ 1,826.99 Million in 2019, projecting it to reach US$ 3,215.94 Million by 2027. This translates to a CAGR of approximately 7.6% during the forecast period.

    What segments are covered in this report?

    The Europe Drug Modelling Software Market report typically cover these key segments-

  • 产品类型 (数据库, 软件)
  • 应用 (药物发现和开发, 计算生理医学, 疾病建模, 医学成像, 药物靶点的预测分析, 模拟软件, 细胞模拟)
  • What is the historic period, base year, and forecast period taken for Europe Drug Modelling Software Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Drug Modelling Software Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in Europe Drug Modelling Software Market?

    The Europe Drug Modelling Software Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Crown Bioscience Inc (JSR life science)
  • Genedata AG
  • Biognos AB
  • Dassault Systèmes
  • Acellera
  • Who should buy this report?

    The Europe Drug Modelling Software Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Drug Modelling Software Market value chain can benefit from the information contained in a comprehensive market report.